RGPX · As filed with the SEC
Regenerex Pharma income statement, by quarter
The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
STATEMENTS OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | Q2 FY25 3 months ended Sep 30, 2025 | Q1 FY24 3 months ended Jun 30, 2025 | Q4 FY24† 3 months ended Mar 31, 2025 | Q3 FY24 3 months ended Dec 31, 2024 |
|---|---|---|---|---|
| Operating Expenses | ||||
| Selling, General and Administrative Expense | 650,277 | 633,783 | 356,825† | 294,130 |
| Research and Development Expense | 136,432 | — | 645,099† | 17,380 |
| Total Operating Expenses | 786,709 | 633,783 | 1,001,924† | 311,510 |
| Operating Loss | (786,709) | (633,783) | (1,001,924)† | (311,510) |
| Other Income (Expense) | ||||
| Interest expense | (22,713) | (23,596) | (4,542)† | (27,016) |
| Foreign currency gain (loss) | — | — | — | 24,000 |
| Foreign Currency Gain/Loss | (539) | (6,092) | — | — |
| Other expense | (4,000) | — | — | — |
| Income Tax Expense | (50) | (113) | — | — |
| Non-Operating Income (Expense) | (27,302) | (29,801) | (408,461)† | (3,016) |
| Net Loss | (814,011) | (663,584) | (1,410,385)† | (314,526) |
| Basic and Diluted Loss per Common Share | 0.00 | 0.00 | — | 0.00 |
| Weighted Average Shares Outstanding | 281,463,410 | 281,123,410 | — | 278,436,236 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.